Prof. Leyla Ozer
4
reviews
14/01/2026
22/09/2025
30/04/2023
Today we came for our annual check-up with Associate Professor Dr. Elif Taşçı Şenocak, and, honestly, I got the impression that I would have received better service even at a public hospital. I could not understand such irritation, gestures, and facial expressions. The doctor's knowledge is very good, but the level of service provided leaves mixed feelings. Unfortunately, for a hospital of this caliber, this does not meet expectations.
19/03/2026
Professor Leyla Ozer is a medical oncologist specializing in gastrointestinal oncology. She works in the dedicated Gastrointestinal Oncology Unit at Acıbadem Atakent Hospital in Istanbul and teaches at Acıbadem Mehmet Ali Aydınlar University.
Her clinical focus is colon and rectal cancer, pancreatic tumors, and esophageal tumors. This is a field that requires close team collaboration with surgeons, radiation oncologists, and interventional radiologists; such a structure is in place at Acıbadem Atakent.
Leyla Ozer’s training follows the classical Turkish oncology pathway: medical degree in 2001, specialization in internal medicine in 2008, subspecialization in medical oncology in 2013 at Istanbul University, Faculty of Medicine.
In her academic work, she participates in modern international research. One of the most recent examples is a multicenter radiomics study in T4 rectal cancer, published in Cancer Medicine (Wiley) in 2025.
For the patient, this means a medical oncologist specifically focused on the “GI direction” at one of the leading private oncology centers in Turkey.
Achievements and Awards
About the doctor
Medical oncology (Tıbbi Onkoloji), a subspecialty after internal medicine.
Narrow focus: gastrointestinal oncology (Gastrointestinal Oncology Unit, Acıbadem Atakent Hospital).
- 2001 — Istanbul University Cerrahpaşa Faculty of Medicine, medical degree (MD)
- 2008 — Istanbul University Istanbul Faculty of Medicine, specialization in internal medicine
- 2013 — Istanbul University Istanbul Faculty of Medicine, subspecialization in medical oncology
Istanbul University Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, Istanbul University Istanbul Medical Faculty (per AVESİS Acıbadem). Exact dates available in public sources are limited.
Currently — Acıbadem Atakent Hospital, Gastrointestinal Oncology Unit; Professor at Acıbadem Mehmet Ali Aydınlar University Medical Faculty.
AVESİS Acıbadem University — personal page.
Cancer Medicine (Wiley), 2025: “Multi-Institutional MR-Derived Radiomics to Predict Post-Exenteration Disease Recurrence in Patients With T4 Rectal Cancer” (co-author; affiliation — Acıbadem University, Atakent Hospital Gastrointestinal Oncology Unit).
In earlier works — co-authorship in publications from her Istanbul Tıp Fakültesi period: a series of papers on lymphomas, on triple-negative breast cancer, immunology, and oncological complications (per the AVESİS Acıbadem list).
According to publicly available official sources at the time of verification, membership in international or national associations has not been confirmed.
Acıbadem Atakent Hospital is a clinic of the Acıbadem Healthcare Group, located in the Küçükçekmece district on the European side of Istanbul. It is a multidisciplinary center that includes an oncology department, a transplantation department, an IVF center, and cardiology and pediatric departments.
For patients with gastrointestinal tumors, Acıbadem Atakent has a dedicated Gastrointestinal Oncology Unit. This is a format in which the patient is managed by a multidisciplinary team: medical oncologist, colorectal surgeon, radiation oncologist, interventional radiologist, and pathologist.
Modern methods for diagnosing and treating colon and rectal cancer are available: high-resolution pelvic MRI, endoscopic methods, laparoscopic and robotic surgeries, radiation therapy (including stereotactic), chemotherapy, targeted therapy, and immunotherapy.
Acıbadem Atakent is the academic base of Acıbadem Mehmet Ali Aydınlar University, so clinical research is actively conducted here. This gives patients access not only to standard treatment but also to new approaches as part of research protocols.
